November is National Alzheimer’s Disease (AD) Awareness Month in the US.
AD is the most common form of dementia: 60-70% of all dementia cases are AD. This is one of the cruelest and life-threatening diseases that impacts memory, movement, behavior and even thinking.
There is still no cure for AD. However, patients can potentially reduce the symptoms with the help of medications.
GCT is a global provider of services for CNS and Neurology clinical studies.
GCT President, Dr Jeffrey T. Apter is a Key Opinion Leader (KOL) in Alzheimer’s Disease. He has been a research collaborator in the Departments of Psychology and the member of the New Jersey Alzheimer Association Scientific Advisory Board, publishing of over 30 articles in the areas of psychiatric and Alzheimer’s research.
Since 2001, GCT conducted numerous AD trials helping pharma and biotech company with their search for medication to cure the disease of fight its symptoms.
Please contact bd@gctrilas.com for more information about AD research.